ARIAD Pharmaceuticals Inc (ARIA)

23.70
0.06 0.23
NASDAQ : Health Care
Prev Close 23.64
Open 23.67
Day Low/High 23.66 / 23.73
52 Wk Low/High 4.37 / 10.07
Volume 8.38M
Avg Volume 10.24M
Exchange NASDAQ
Shares Outstanding 194.20M
Market Cap 4.60B
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of ARIAD Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of ARIAD Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of ARIAD...

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.

The Merger Frenzy Is On: Here's What to Expect from the Rest of 2017

The Merger Frenzy Is On: Here's What to Expect from the Rest of 2017

This year's profitable trends look to persist into 2017.

These Stocks Are Too Hot, in a Bad Way : Jim Cramer's 'Mad Money' Recap

These Stocks Are Too Hot, in a Bad Way : Jim Cramer's 'Mad Money' Recap

Going into earnings what the market needs now is more negativity, Cramer says.

Cramer: Stocks Need to Cool Down

Cramer: Stocks Need to Cool Down

With earnings season approaching, some negativity would be nice.

The Real Apple of the Dow's Eye -- ICYMI

The Real Apple of the Dow's Eye -- ICYMI

McDonald's announces its intentions to sell its China business to a group including Carlyle Group as Apple celebrates the iPhone's 10th birthday. Plus Trump's latest meetings.

Nasdaq Separates Itself From the Rest of the Market

Nasdaq Separates Itself From the Rest of the Market

Narrowing strength becomes a concern.

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

The $5.2 billion takeout of Ariad Pharma was the biggest news from the closely followed healthcare conference.

Nasdaq Hits Records Even as Crude Selloff Sours Rest of Market

Nasdaq Hits Records Even as Crude Selloff Sours Rest of Market

A selloff in crude oil proves another roadblock in the Dow Jones Industrial Average's pursuit of 20,000.

Facebook Makes Powerful Move Higher -- How to Trade It, Along With 6 Other Active Stocks

Facebook Makes Powerful Move Higher -- How to Trade It, Along With 6 Other Active Stocks

Put a charge in your portfolio this week.

Takeda Acquires Ariad Pharmaceuticals in $5.2 Billion Deal

Takeda Acquires Ariad Pharmaceuticals in $5.2 Billion Deal

Shares of Ariad Pharmaceuticals soared Monday after Japan's Takeda Pharmaceutical offered to buy the leukemia drug maker.

Midday Report: Ariad Pharmaceuticals Jumps on Deal; Dow Takes Pause on Road to 20,000

Midday Report: Ariad Pharmaceuticals Jumps on Deal; Dow Takes Pause on Road to 20,000

Stocks trade mostly lower with the Dow Jones Industrial Average taking a pause in its race toward 20,000.

Noteworthy Monday Option Activity: ARIA, DFRG, AYI

Noteworthy Monday Option Activity: ARIA, DFRG, AYI

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in ARIAD Pharmaceuticals Inc , where a total of 23,103 contracts have traded so far, representing approximately 2.3 million underlying shares. That amounts to about 67.5% of ARIA's average daily trading volume over the past month of 3.4 million shares.

Takeda Pays $5.2 Billion for Leukemia Drug Maker Ariad, Ending Months of Takeout Speculation

Takeda Pays $5.2 Billion for Leukemia Drug Maker Ariad, Ending Months of Takeout Speculation

Ariad's primary drugs are leukemia treatment Iclusig and Brigatinib, an investigational drug product targeting non-small cell lung cancer.

Dow Steps Back From 20,000 as Crude Selloff Weighs on Energy Sector

Dow Steps Back From 20,000 as Crude Selloff Weighs on Energy Sector

Stocks trade mostly lower Monday with the Dow Jones Industrial Average taking a pause in its race toward 20,000.

Stock Picks Are Hard to Find as Small-Caps Struggle

Stock Picks Are Hard to Find as Small-Caps Struggle

With poor breadth and money managers hiding in large-caps, I am being cautious, right now.

Biotech Stocks Surge Monday Amid Flurry of Deal Activity

Biotech Stocks Surge Monday Amid Flurry of Deal Activity

Deals, though, weren't the only mover of share prices.

Stock Futures Mostly Lower as Crude Oil Slides Below $53

Stock Futures Mostly Lower as Crude Oil Slides Below $53

Stock futures mostly lower Monday morning amid a slump in crude oil prices.

ARIAD Enters Into Definitive Agreement To Be Acquired By Takeda For $5.2 Billion

ARIAD Enters Into Definitive Agreement To Be Acquired By Takeda For $5.2 Billion

ARIAD Pharmaceuticals (NASDAQ:ARIA) ("ARIAD") today announced it has entered into a definitive agreement to be acquired by Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") under which Takeda will acquire all of...

Takeda To Acquire ARIAD Pharmaceuticals, Inc.

Takeda To Acquire ARIAD Pharmaceuticals, Inc.

Takeda Pharmaceutical Company Limited (TSE:4502) ("Takeda") and ARIAD Pharmaceuticals, Inc.

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.

ARIAD To Present At The 35th Annual J.P. Morgan Healthcare Conference

ARIAD To Present At The 35th Annual J.P. Morgan Healthcare Conference

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), a rare cancer-focused innovative biotechnology company, today announced that it will present at the 35th Annual J.

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.